Crescent Biopharma Inc.
CBIO | NASDAQ
$13.53
-$0.54 (-3.84%)
At close: Oct 30, 2026, 3:59 PM ET
$13.48
-$0.05 (-0.37%)
After-hours:
Oct 30, 2026, 4:18 PM ET
Company Profile
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| Joshua T. Brumm | Chief Executive Officer & Director |
| Jonathan McNeill | President & Chief Operating Officer |
| Richard William Scalzo | Chief Financial Officer |
| Amy Reilly | Chief Communications Officer |
| Barbara H. Bispham | General Counsel & Corporate Secretary |
| Christopher Doughty | Chief Business Officer |
| Ellie Im | Chief Medical Officer |
| Jan Pinkas | Chief Scientific Officer |
| Ryan Lynch | Senior Vice President of Finance, Treasurer & Chief Accounting Officer |
| Wenjie Cheng | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | 4 | Filing |
| Sep 18, 2026 | S-8 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 31, 2026 | EFFECT | Filing |
Crescent Biopharma Inc.
| Country | United States |
| IPO Date | Jan 10, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 44 |
| CEO | Joshua T. Brumm |
Contact Details
300 Fifth Avenue Waltham,
Massachusetts 02451 United States
Stock Details
| Ticker Symbol | CBIO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001253689 |
| CUSIP Number | G2545C104 |
| ISIN Number | KYG2545C1042 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove CBIO